Site Search

Search
Showing 1 - 10 of 22 results
About the CF Foundation | CFTR Modulators | Genetic Therapies
New Cystic Fibrosis Drug Brings Gift of a Future, NPR Reports Online
News |
| 1 min read
About the CF Foundation | CFTR Modulators | Genetic Therapies
New Hope of Kalydeco (VX-770) Makes Headlines and Newscasts Around the Nation
News |
| 2 min read
About the CF Foundation | CFTR Modulators | Genetic Therapies
The New York Times and Other Major Media Outlets Feature Results of VX-770 Trial
News |
| 2 min read
About the CF Foundation | CFTR Modulators | Genetic Therapies
Wall Street Journal Health Blog: CF Foundation Not Just a Cheerleader
News |
| 2 min read
About the CF Foundation | CFTR Modulators | Genetic Therapies
Foundation Makes Milestone Payment to Collaborator for Potential Dual-Acting Compound
News |
| 1 min read
About the CF Foundation | Genetic Therapies | CFTR Modulators
Foundation Showcased in BusinessWeek
News |
| 1 min read
About the CF Foundation | CFTR Modulators | Genetic Therapies
Promising Data For CF Drug Published in The Lancet
News |
| 1 min read
About the CF Foundation | Genetic Therapies | Research
Science Magazine Spotlights 20 Years of CF Research
News |
| 1 min read
About the CF Foundation | CFTR Modulators | Genetic Therapies
Foundation Makes Milestone Payment to EPIX Pharmaceuticals
News |
| 1 min read
About the CF Foundation | CFTR Modulators | Genetic Therapies
FDA Expands Use of Orkambi® to Children Ages 6 to 11 With CF

The U.S. Food and Drug Administration (FDA) approved the use of lumacaftor/ivacaftor (Orkambi®) today for children with cystic fibrosis ages 6 to 11, who have two copies of the F508del mutation.

News |
| 2 min read